Navigation Links
Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
Date:5/21/2009

hat chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. The Company was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
2. Agendia Joins the Personalized Medicine Coalition (PMC)
3. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
4. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
5. Agendia BV Appoints Clinical and Scientific Advisory Board
6. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
7. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
8. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
9. Agendia Appoints New Chief Financial Officer
10. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
11. Agendia Appoints VP of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ... new report "Cell Therapy - Technologies, Markets ... This report describes and evaluates cell therapy technologies ... an important role in the practice of medicine. ... fashioned bone marrow transplants. Role of cells in ...
(Date:5/28/2015)... 28, 2015 DryLet, LLC a ... applications such as animal waste reduction, bioremediation, wastewater ... in wastewater treatment plants and restaurant kitchen settings, ... Pork Expo, June 3-5 in Des Moines, Iowa. ... a Wall Street Journal article because of its ...
(Date:5/28/2015)... , May 28, 2015  GenVec, Inc. (Nasdaq: ... CEO, Douglas J. Swirsky , will present a ... at 11 a.m. EDT on Thursday, June 4, 2015. ... Mr. Swirsky,s presentation will be available at the following ... available on GenVec,s website.  To access, visit www.genvec.com ...
(Date:5/28/2015)... Minneapolis, MN (PRWEB) May 28, 2015 ... makes it a point to ask his audiences ... of future trends including robotics, solar cells, fuel ... sequencing, 3D printers, advanced battery storage technology, driverless ... assistants, and high-quality but inexpensive online education. ...
Breaking Biology Technology:Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2GenVec To Present At The Jefferies Healthcare Conference 2Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2
... Baxter Healthcare Corporation,today announced its V-Link ... first needleless intravenous (IV) connector to,contain an ... in the,United States and Canada. V-Link with ... 99.9 percent or more of specific common ...
... discussed during Omnicell,educational, programs April 15 at ... The Mid-America Club in Chicago, MOUNTAIN ... Inc. (Nasdaq: OMCL ), a leading provider,of ... in,healthcare facilities, and Rice Memorial Hospital today announced ...
... Collins, M.D., Ph.D. a,physician-geneticist and leader of ... of the inaugural Inamori Ethics Prize from ... at Case Western Reserve,University., (Photo: ... Prize honors outstanding international ethical,leaders. It is ...
Cached Biology Technology:Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 2Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 3Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 4Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell 2Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell 3Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 2Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 3Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 4
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
(Date:5/18/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Bethesda, MD FASEB MARC (Maximizing Access to ... for the 2012 American Society for Clinical Investigation/Association of ... April 27-29, 2012. These awards are meant to ... scientists into the mainstream of the basic science community ...
... the crypt are supposed to be scary, but new ... and colleagues shows that crypts can be places of ... are small areas of the intestine where new cells ... By focusing on one protein expressed in our intestines ...
... , The decline of Caribbean coral reefs has been linked ... research led by scientists at Scripps Institution of Oceanography at ... news humans are still to blame. The good news ... decline. Employing a novel excavation technique to reconstruct the ...
Cached Biology News:Tales from the crypt lead researchers to cancer discovery 2Declines in Caribbean coral reefs pre-date damage resulting from climate change 2Declines in Caribbean coral reefs pre-date damage resulting from climate change 3
...
...
...
... submicron range are part of your production ... of particle size is important to you. ... detect the component populations in your sample ... Analyzer uses Photon Correlation Spectroscopy (PCS) , ...
Biology Products: